prop think

Interesting information

http://www.nasdaq.com/press-release/propthink-to-host-special-conference-call-with-sunshine-heart-ceo-20130828-00429

Why We're Interviewing Sunshine Heart

Shares of Sunshine Heart have appreciated significantly in the past four months, up over 140% since the company's mid-April capital raise, as healthcare investors have taken particular note of this small-cap medical device developer. Sunshine Heart's developmental C-Pulse Heart Assist device offers a novel approach to the treatment of late-stage congestive heart failure, and an early feasibility study completed in 2011 demonstrated that the device provided a strong benefit in a historically difficult-to-treat patient population. Heart failure patients in the early study have seen the severity of their disease improve drastically with time on the device, so much so in fact, that C-Pulse is arguably reversing the latter stages of congestive heart failure -- two of 20 patients have already been weaned from the product, and Sunshine Heart is evaluating more patients for complete removal of the implanted heart assist system. Now, a large pivotal trial being run in the United States and a second, smaller trial running concurrently in Europe are designed to bring the device through the approval process, and subsequently, to the thousands of patients suffering from late-stage heart failure in the U.S. and Europe.

Read more: http://www.nasdaq.com/press-release/propthink-to-host-special-conference-call-with-sunshine-heart-ceo-20130828-00429#ixzz2dIx0wKJH